
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Management of Adverse Reactions to Loncastuximab in Patients With Relapsed or Refractory Diffuse Large B‐Cell Lymphoma - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E4813E8AEEC3D305813E001101AEB9.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="blackwellopen">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368254/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Hematological Oncology">
<meta name="citation_title" content="Management of Adverse Reactions to Loncastuximab in Patients With Relapsed or Refractory Diffuse Large B‐Cell Lymphoma">
<meta name="citation_author" content="Narendranath Epperla">
<meta name="citation_author_institution" content="Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA">
<meta name="citation_author" content="Adam J Olszewski">
<meta name="citation_author_institution" content="Division of Hematology and Oncology, Brown University Health, Providence, Rhode Island, USA">
<meta name="citation_author" content="Emily C Ayers">
<meta name="citation_author_institution" content="Division of Hematology and Oncology, University of Virginia Health System, Charlottesville, Virginia, USA">
<meta name="citation_author" content="Sairah Ahmed">
<meta name="citation_author_institution" content="Department of Lymphoma/Myeloma and Stem Cell Transplantation &amp; Cellular Therapy, UT MD Anderson Cancer Center, Houston, Texas, USA">
<meta name="citation_publication_date" content="2025 Aug 20">
<meta name="citation_volume" content="43">
<meta name="citation_issue" content="5">
<meta name="citation_firstpage" content="e70128">
<meta name="citation_doi" content="10.1002/hon.70128">
<meta name="citation_pmid" content="40836271">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368254/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368254/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368254/pdf/HON-43-e70128.pdf">
<meta name="description" content="Diffuse large B‐cell lymphoma (DLBCL) is the most common B‐cell non‐Hodgkin lymphoma in the world. Treatment options for relapsed DLBCL in the third line and beyond include chimeric antigen receptor T‐cell therapy, T‐cell–engaging bispecific ...">
<meta name="og:title" content="Management of Adverse Reactions to Loncastuximab in Patients With Relapsed or Refractory Diffuse Large B‐Cell Lymphoma">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Diffuse large B‐cell lymphoma (DLBCL) is the most common B‐cell non‐Hodgkin lymphoma in the world. Treatment options for relapsed DLBCL in the third line and beyond include chimeric antigen receptor T‐cell therapy, T‐cell–engaging bispecific ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368254/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12368254">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1002/hon.70128"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/HON-43-e70128.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12368254%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12368254/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12368254/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368254/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-blackwellopen.png" alt="Wiley Open Access Collection logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Wiley Open Access Collection" title="Link to Wiley Open Access Collection" shape="default" href="https://doi.org/10.1002/hon.70128" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Hematol Oncol</button></div>. 2025 Aug 20;43(5):e70128. doi: <a href="https://doi.org/10.1002/hon.70128" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1002/hon.70128</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Hematol%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hematol%20Oncol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Hematol%20Oncol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Hematol%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Management of Adverse Reactions to Loncastuximab in Patients With Relapsed or Refractory Diffuse Large B‐Cell Lymphoma</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Epperla%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Narendranath Epperla</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Narendranath Epperla</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Epperla%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Narendranath Epperla</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Olszewski%20AJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Adam J Olszewski</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Adam J Olszewski</span></h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Division of Hematology and Oncology, Brown University Health, Providence, Rhode Island, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Olszewski%20AJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Adam J Olszewski</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ayers%20EC%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Emily C Ayers</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Emily C Ayers</span></h3>
<div class="p">
<sup>
<sup>3</sup>
</sup>Division of Hematology and Oncology, University of Virginia Health System, Charlottesville, Virginia, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ayers%20EC%22%5BAuthor%5D" class="usa-link"><span class="name western">Emily C Ayers</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ahmed%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Sairah Ahmed</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Sairah Ahmed</span></h3>
<div class="p">
<sup>
<sup>4</sup>
</sup>Department of Lymphoma/Myeloma and Stem Cell Transplantation &amp; Cellular Therapy, UT MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ahmed%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sairah Ahmed</span></a>
</div>
</div>
<sup>4</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="hon70128-aff-0001">
<sup>
<sup>1</sup>
</sup>Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA</div>
<div id="hon70128-aff-0002">
<sup>
<sup>2</sup>
</sup>Division of Hematology and Oncology, Brown University Health, Providence, Rhode Island, USA</div>
<div id="hon70128-aff-0003">
<sup>
<sup>3</sup>
</sup>Division of Hematology and Oncology, University of Virginia Health System, Charlottesville, Virginia, USA</div>
<div id="hon70128-aff-0004">
<sup>
<sup>4</sup>
</sup>Department of Lymphoma/Myeloma and Stem Cell Transplantation &amp; Cellular Therapy, UT MD Anderson Cancer Center, Houston, Texas, USA</div>
<div class="author-notes p">
<div class="fn" id="correspondenceTo">
<sup>*</sup><p class="display-inline">

<strong>Correspondence:</strong> Narendranath Epperla, 
(<span>naren.epperla@hci.utah.edu</span>)
</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Revised 2025 Jul 3; Received 2025 May 28; Accepted 2025 Aug 11; Issue date 2025 Sep.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s). <em>Hematological Oncology</em> published by John Wiley &amp; Sons Ltd.</div>
<p>This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12368254  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40836271/" class="usa-link">40836271</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>ABSTRACT</h2>
<p>Diffuse large B‐cell lymphoma (DLBCL) is the most common B‐cell non‐Hodgkin lymphoma in the world. Treatment options for relapsed DLBCL in the third line and beyond include chimeric antigen receptor T‐cell therapy, T‐cell–engaging bispecific antibodies, and loncastuximab tesirine (loncastuximab tesirine‐lpyl [Lonca]), each with unique toxicity profiles. There is still an unmet need for guidance on managing Lonca‐associated adverse events (AEs), particularly for oncologists who have limited experience with this antibody–drug conjugate. Here, an online survey among lymphoma specialists in the US between June and August 2024 assessed practice patterns and experiences, including Lonca treatment patterns, AE management, patient concerns, and physician perceptions. Based on these responses, an algorithm was developed to help manage Lonca‐associated AEs. The most commonly reported AEs were edema and rash/photosensitivity, typically occurring within the first 4 doses, whereas fatigue was the most common patient concern. Lonca‐associated AEs were managed by delaying or discontinuing Lonca or by prescribing diuretics, steroids, or antihistamines, depending on the AE observed. The survey results align with findings from prior clinical trials and support the manageability of Lonca‐associated AEs in a wide variety of settings. The included algorithm provides guidance for managing AEs, such as edema, myelosuppression, and cutaneous reactions.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> adverse events, cutaneous reactions, diffuse large B‐cell lymphoma, effusion, loncastuximab tesirine</p></section></section><section id="hon70128-sec-0010"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Diffuse large B‐cell lymphoma (DLBCL) is the most common aggressive type of non‐Hodgkin lymphoma, accounting for approximately 31% of adult cases [<a href="#hon70128-bib-0001" class="usa-link" aria-describedby="hon70128-bib-0001">1</a>, <a href="#hon70128-bib-0002" class="usa-link" aria-describedby="hon70128-bib-0002">2</a>]. The standard first‐line treatments for DLBCL include regimens such as rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) or pola‐R‐CHP (wherein vincristine is replaced by polatuzumab vedotin), which have cure rates of approximately 53% to more than 70% [<a href="#hon70128-bib-0003" class="usa-link" aria-describedby="hon70128-bib-0003">3</a>, <a href="#hon70128-bib-0004" class="usa-link" aria-describedby="hon70128-bib-0004">4</a>, <a href="#hon70128-bib-0005" class="usa-link" aria-describedby="hon70128-bib-0005">5</a>, <a href="#hon70128-bib-0006" class="usa-link" aria-describedby="hon70128-bib-0006">6</a>, <a href="#hon70128-bib-0007" class="usa-link" aria-describedby="hon70128-bib-0007">7</a>]. However, approximately 40% of patients with DLBCL have disease that eventually relapses following first‐line treatment [<a href="#hon70128-bib-0008" class="usa-link" aria-describedby="hon70128-bib-0008">8</a>].</p>
<p>For patients with relapsed or refractory (R/R) DLBCL, second‐line treatment options include chimeric antigen receptor T‐cell therapy (CAR‐T) (i.e., axicabtagene ciloleucel and lisocabtagene maraleucel) for patients with primary refractory disease or DLBCL that relapses within 1 year of first‐line therapy [<a href="#hon70128-bib-0003" class="usa-link" aria-describedby="hon70128-bib-0003">3</a>, <a href="#hon70128-bib-0009" class="usa-link" aria-describedby="hon70128-bib-0009">9</a>, <a href="#hon70128-bib-0010" class="usa-link" aria-describedby="hon70128-bib-0010">10</a>]. For subsequent lines of treatment, options include cellular therapies, such as CAR‐T; T‐cell–engaging bispecific antibodies; antibody–drug conjugates (ADCs), such as loncastuximab tesirine (loncastuximab tesirine‐lpyl [Lonca]) and polatuzumab‐vedotin; monoclonal antibody combinations (i.e., tafasitamab plus lenalidomide); small‐molecule inhibitors, such as selinexor; and combination therapies, including lenalidomide/rituximab/brentuximab vedotin [<a href="#hon70128-bib-0003" class="usa-link" aria-describedby="hon70128-bib-0003">3</a>, <a href="#hon70128-bib-0011" class="usa-link" aria-describedby="hon70128-bib-0011">11</a>, <a href="#hon70128-bib-0012" class="usa-link" aria-describedby="hon70128-bib-0012">12</a>, <a href="#hon70128-bib-0013" class="usa-link" aria-describedby="hon70128-bib-0013">13</a>, <a href="#hon70128-bib-0014" class="usa-link" aria-describedby="hon70128-bib-0014">14</a>, <a href="#hon70128-bib-0015" class="usa-link" aria-describedby="hon70128-bib-0015">15</a>, <a href="#hon70128-bib-0016" class="usa-link" aria-describedby="hon70128-bib-0016">16</a>, <a href="#hon70128-bib-0017" class="usa-link" aria-describedby="hon70128-bib-0017">17</a>, <a href="#hon70128-bib-0018" class="usa-link" aria-describedby="hon70128-bib-0018">18</a>]. In patients with late relapses (&gt; 1 year following the completion of first‐line chemoimmunotherapy), autologous hematopoietic cell transplantation could be considered should they achieve chemosensitivity [<a href="#hon70128-bib-0019" class="usa-link" aria-describedby="hon70128-bib-0019">19</a>, <a href="#hon70128-bib-0020" class="usa-link" aria-describedby="hon70128-bib-0020">20</a>]. Despite all the available treatments, challenges remain with existing regimens, including high relapse rates and an unmet need for new therapeutic options. There is a need for targeted therapies with manageable adverse event (AE) profiles that can be used in the community setting and for older and/or less fit patients.</p>
<p>Lonca is an ADC comprised of a humanized anti‐CD19 antibody conjugated via a linker region to a pyrrolobenzodiazepine (PBD) dimer cytotoxin [<a href="#hon70128-bib-0021" class="usa-link" aria-describedby="hon70128-bib-0021">21</a>, <a href="#hon70128-bib-0022" class="usa-link" aria-describedby="hon70128-bib-0022">22</a>]. Upon binding to CD19, Lonca is internalized, the linker is cleaved, and the PBD dimers are released [<a href="#hon70128-bib-0022" class="usa-link" aria-describedby="hon70128-bib-0022">22</a>, <a href="#hon70128-bib-0023" class="usa-link" aria-describedby="hon70128-bib-0023">23</a>]. The PBD dimers bind to DNA and form cytotoxic DNA crosslinks, which lead to blocked cell division and subsequent cancer cell apoptosis [<a href="#hon70128-bib-0022" class="usa-link" aria-describedby="hon70128-bib-0022">22</a>, <a href="#hon70128-bib-0023" class="usa-link" aria-describedby="hon70128-bib-0023">23</a>]. Lonca received accelerated approval from the United States (US) Food and Drug Administration in April 2021 as a single agent for the treatment of adult patients with R/R DLBCL after two or more lines of systemic therapy, including for DLBCL not otherwise specified, DLBCL arising from low‐grade lymphoma, and high‐grade B‐cell lymphoma [<a href="#hon70128-bib-0024" class="usa-link" aria-describedby="hon70128-bib-0024">24</a>].</p>
<p>Lonca's pivotal, open‐label, single‐arm, Phase 2 LOTIS‐2 trial (<a href="https://clinicaltrials.gov/ct2/show/NCT03589469" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03589469</a>) included 145 participants with R/R DLBCL, had a median follow‐up of 7.8 months, an overall response rate (ORR) of 48.3% (95% CI: 39.9–56.7), and a complete response rate of 24.8% [<a href="#hon70128-bib-0012" class="usa-link" aria-describedby="hon70128-bib-0012">12</a>, <a href="#hon70128-bib-0025" class="usa-link" aria-describedby="hon70128-bib-0025">25</a>]. In the LOTIS‐2 trial, treatment‐emergent adverse events (TEAEs) considered likely to be related to the PBD payload included edema or effusion (31% of patients), skin or nail‐related AEs (43%), and liver enzyme abnormalities (51%), with PBD‐related AEs generally being grade 1 or 2 in severity [<a href="#hon70128-bib-0012" class="usa-link" aria-describedby="hon70128-bib-0012">12</a>]. Most patients were able to continue treatment, with some requiring dose delays. Patients received oral dexamethasone premedication to prevent PBD‐related toxicities (i.e., edema and rash) unless contraindicated and were advised to avoid prolonged sun exposure and to report potential skin rashes. To manage AEs, treatment delays of up to 5 weeks and dose reductions were allowed, and patients with weight gain over 1 kg from day 1 of cycle 1 or with edema/pleural effusions were treated with spironolactone [<a href="#hon70128-bib-0012" class="usa-link" aria-describedby="hon70128-bib-0012">12</a>].</p>
<p>Updated safety analyses demonstrated that an all‐grade TEAE occurred in 98.6% of patients, and TEAEs occurring in ≥ 30% of the all‐treated population were increased gamma‐glutamyl transferase (GGT; 42%), neutropenia (40%), and thrombocytopenia (33%) [<a href="#hon70128-bib-0025" class="usa-link" aria-describedby="hon70128-bib-0025">25</a>]. Grade ≥ 3 TEAEs were reported in 73.8% of patients, and those reported in ≥ 10% of the all‐treated population were neutropenia (26%), thrombocytopenia (18%), increased GGT (17%) and anemia (10%). TEAEs leading to treatment discontinuation occurred in 24.8% of patients in the all‐treated population, with the most common being GGT (12.4%), peripheral edema (2.8%), localized edema (2.1%), and pleural effusion (2.1%). No increase in toxicity was observed in older patients compared with younger patients [<a href="#hon70128-bib-0025" class="usa-link" aria-describedby="hon70128-bib-0025">25</a>].</p>
<p>Real‐world studies have been conducted to investigate Lonca utilization and treatment settings [<a href="#hon70128-bib-0026" class="usa-link" aria-describedby="hon70128-bib-0026">26</a>, <a href="#hon70128-bib-0027" class="usa-link" aria-describedby="hon70128-bib-0027">27</a>]. A study of 118 patients with R/R DLBCL who received third‐line Lonca following second‐line CAR‐T (<em>n</em> = 95) or fourth‐line Lonca following third‐line CAR‐T (<em>n</em> = 23) demonstrated an ORR of 73% and 78%, respectively [<a href="#hon70128-bib-0026" class="usa-link" aria-describedby="hon70128-bib-0026">26</a>]. A retrospective chart review presented data from 187 patients with R/R DLBCL from 21 US centers who had received Lonca as a second‐ or third‐line (19%) or fourth‐line and beyond (81%) therapy [<a href="#hon70128-bib-0027" class="usa-link" aria-describedby="hon70128-bib-0027">27</a>]. Most of the patients had received prior CAR‐T (60%), but only 16% had received prior autologous stem cell therapy. AEs were documented in 35% of patients with AEs of interest, including cytopenias (17%), peripheral edema (11%), rash (10%), pleural effusion (3%), and pericardial effusion (0.5%). Treatments reported after Lonca therapy included immunochemotherapy (31%), tafasitamab‐lenalidomide (17%), and CAR‐T (10%) [<a href="#hon70128-bib-0027" class="usa-link" aria-describedby="hon70128-bib-0027">27</a>].</p>
<p>Despite increasing data availability, there remains an unmet need for comprehensive guidance on Lonca's current usage patterns, clinical management, and Lonca‐associated AEs, particularly for oncologists practicing in the community setting who may have limited clinical experience with Lonca. This article provides clinical practice recommendations for managing AEs commonly associated with Lonca treatment in patients with R/R DLBCL based on the real‐world experience of clinicians who have adopted Lonca into their practice and gained expertise in practical management of its AEs.</p></section><section id="hon70128-sec-0020"><h2 class="pmc_sec_title">2. Materials and Methods</h2>
<section id="hon70128-sec-0030"><h3 class="pmc_sec_title">2.1. Survey Development</h3>
<p>An online questionnaire was developed to assess the practice patterns and clinical experience of hematologists using Lonca in the treatment of R/R DLBCL. The survey was distributed via email to lymphoma specialists at academic institutions located across the US. The survey contained 51 questions, 44 of which were quantitative, offering single or multiple‐choice responses, while 7 were qualitative, allowing for open‐ended feedback. The questionnaire and its administration plan were designed and reviewed by the authors.</p>
<p>The survey covered several key domains, beginning with respondent characteristics, which included age, gender, race/ethnicity, geographic location, and practice details to assess the representativeness of the respondents. Lonca treatment patterns were explored, including its sequencing with other therapies, such as CAR‐T, autologous/allogeneic transplantation, and bispecific antibodies. Factors influencing treatment initiation, duration, and discontinuation were also investigated. The AE patterns and patient counseling domain focused on identifying the most common and severe AEs associated with Lonca, the number of doses before AE onset, and which AEs led to dose reductions, delays, or discontinuations. Additionally, the questionnaire explored how physicians counseled patients regarding potential AEs. Specific questions addressed the management of Lonca‐associated AEs, including prophylactic dexamethasone use for edema/effusion and the occurrence of peripheral edema, pleural or pericardial effusions, myelosuppression, and cutaneous reactions, such as rashes and photosensitivity. The final domain examined common patient concerns and physician perceptions of Lonca's safety profile.</p></section><section id="hon70128-sec-0040"><h3 class="pmc_sec_title">2.2. Study Sample</h3>
<p>The study targeted oncologists specializing in the treatment of DLBCL, who are currently in clinical practice. To be included in the full analysis, respondents were required to practice oncology within the US and have prior experience prescribing Lonca.</p></section><section id="hon70128-sec-0050"><h3 class="pmc_sec_title">2.3. Recruitment of Respondents</h3>
<p>The online survey was administered via the survey website SurveyMonkey (San Mateo, CA) between June 24, 2024, and August 16, 2024. No financial incentives were provided, and pilot testing estimated the survey completion time to be approximately 30 min.</p></section><section id="hon70128-sec-0060"><h3 class="pmc_sec_title">2.4. Ethics Approval and Consent to Participate</h3>
<p>The study was conducted in compliance with the Declaration of Helsinki. Given the nature of the study (survey), this study was exempt from Institutional Review Board requirements, and informed consent was waived.</p></section><section id="hon70128-sec-0070"><h3 class="pmc_sec_title">2.5. Data Analysis</h3>
<p>Summary descriptive analyses, including mean and median values with ranges, were calculated for survey responses. No statistical significance tests were conducted. Respondents not currently treating patients with Lonca were included in the respondent characteristics analysis but excluded from Lonca use–related analyses.</p>
<p>For Lonca sequencing, responses of “never” were categorized as no, while other responses (i.e., “rarely,” “sometimes,” “often,” and “most of the time”) were categorized as yes. Free‐response qualitative answers were grouped when applicable. For questions on AEs leading to Lonca dosage adjustments, bone marrow suppression‐related responses (i.e., myelosuppression, cytopenia, and neutropenia) were grouped, as were those related to fluid retention (i.e., edema and third spacing).</p></section></section><section id="hon70128-sec-0080"><h2 class="pmc_sec_title">3. Results</h2>
<section id="hon70128-sec-0090"><h3 class="pmc_sec_title">3.1. Respondent Characteristics</h3>
<p>Sixteen physicians responded to the survey. The demographic and practice details of respondents are listed in Table <a href="#hon70128-tbl-0001" class="usa-link">1</a>. A substantial proportion of respondents identified as female (31%) and non‐White (31%). Most of the respondents had been in practice for 6 or more years post‐fellowship (69%). The respondents were from practices across various regions of the US, including the Northeast (i.e., Connecticut, Rhode Island, New York, and Pennsylvania), South (i.e., Virginia, North Carolina, Florida, and Texas), Midwest (i.e., Ohio and Missouri), and West (i.e., Colorado, Utah, and California). Most respondents practiced at universities or academic hospitals (94%) with the ability to administer CAR‐T and/or stem cell transplants.</p>
<section class="tw xbox font-sm" id="hon70128-tbl-0001"><h4 class="obj_head">TABLE 1.</h4>
<div class="caption p"><p>Respondent characteristics.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Characteristic</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Survey respondents (<em>N</em> = 16)</th>
</tr></thead>
<tbody valign="top">
<tr><td colspan="2" align="left" valign="top" rowspan="1">Sex, <em>n</em> (%)</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Male</td>
<td align="center" valign="top" rowspan="1" colspan="1">10 (62.5)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Female</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (31.3)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Did not to answer</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (6.3)</td>
</tr>
<tr><td colspan="2" align="left" valign="top" rowspan="1">Race/ethnicity, <em>n</em> (%)</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">White</td>
<td align="center" valign="top" rowspan="1" colspan="1">9 (56.3)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Asian</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 (25.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hispanic</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (6.3)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Did not answer</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (12.5)</td>
</tr>
<tr><td colspan="2" align="left" valign="top" rowspan="1">Years in practice post‐fellowship, <em>n</em> (%)</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">≤ 5 years</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (31.3)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">6–10 years</td>
<td align="center" valign="top" rowspan="1" colspan="1">7 (43.8)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&gt; 10 years</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 (25.0)</td>
</tr>
<tr><td colspan="2" align="left" valign="top" rowspan="1">Practice setting, <em>n</em> (%)</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">University/academic hospital</td>
<td align="center" valign="top" rowspan="1" colspan="1">15 (93.8)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Community practice associated with an academic hospital</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (6.3)</td>
</tr>
<tr><td colspan="2" align="left" valign="top" rowspan="1">Practice type, <em>n</em> (%)</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Nontransplant, lymphoma‐focused practice</td>
<td align="center" valign="top" rowspan="1" colspan="1">6 (37.5)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Combined lymphoma and transplant/cell therapy practice</td>
<td align="center" valign="top" rowspan="1" colspan="1">10 (62.5)</td>
</tr>
<tr><td colspan="2" align="left" valign="top" rowspan="1">Cellular therapy capability at practice, <em>n</em> (%)</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">CAR‐T therapy and transplant</td>
<td align="center" valign="top" rowspan="1" colspan="1">15 (93.8)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Transplant only</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (6.3)</td>
</tr>
<tr><td colspan="2" align="left" valign="top" rowspan="1">Number of patients with DLBCL seen in each line of therapy in the last year, <em>mean (range)</em>
</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">First line</td>
<td align="center" valign="top" rowspan="1" colspan="1">25 (8–60)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Second line</td>
<td align="center" valign="top" rowspan="1" colspan="1">20 (1–55)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Third line or later</td>
<td align="center" valign="top" rowspan="1" colspan="1">18 (0–50)</td>
</tr>
<tr><td colspan="2" align="left" valign="top" rowspan="1">Number of patients with DLBCL treated with Lonca, <em>n</em> (%)</td></tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1–5</td>
<td align="center" valign="top" rowspan="1" colspan="1">7 (43.8)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">6–10</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (31.3)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">11–20</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (12.5)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">21–30</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (6.3)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&gt; 30</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Unsure</td>
<td align="center" valign="top" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Have never used Lonca</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (6.3)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/hon70128-tbl-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="hon70128-note-0002"><p>Abbreviations: CAR‐T, chimeric antigen receptor T‐cell therapy; DLBCL, diffuse large B‐cell lymphoma; Lonca, loncastuximab tesirine.</p></div></div></section><p>In total, 44% of respondents reported treating between 1 and 5 patients with DLBCL with Lonca (Table <a href="#hon70128-tbl-0001" class="usa-link">1</a>). Respondents reported seeing an average of 25 DLBCL patients in the first‐line setting (range, 8–60 patients), 20 patients in second‐line setting (range, 1–55 patients), and 18 patients in third‐line setting or later (range, 0–50 patients) in the last year. Of the 16 respondents, 15 (94%) had experience with Lonca and were included in the full‐response analysis.</p></section><section id="hon70128-sec-0100"><h3 class="pmc_sec_title">3.2. Lonca Treatment Patterns</h3>
<p>Lonca was used by the respondents in a variety of settings, both before and after other CD19‐directed therapies, and both on‐label and off‐label (e.g., as a second‐line bridging therapy), highlighting the versatility of the use of the agent. More respondents indicated having used Lonca after versus before CAR‐T (100% vs. 53%, respectively), autologous stem cell transplants (73% after vs. 33% before), and bispecific antibodies (87% after vs. 80% before) (Figure <a href="#hon70128-fig-0001" class="usa-link">1A</a>). In contrast, more respondents indicated using Lonca before versus after allogeneic stem cell transplants (53% vs. 20%).</p>
<figure class="fig xbox font-sm" id="hon70128-fig-0001"><h4 class="obj_head">FIGURE 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dec8/12368254/ba8804970886/HON-43-e70128-g003.jpg" loading="lazy" id="jats-graphic-1" height="382" width="709" alt="FIGURE 1"></p>
<div class="p text-right font-secondary"><a href="figure/hon70128-fig-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Lonca treatment patterns, including (A) the use of Lonca to treat relapsed/refractory DLBCL before or after other treatments, (B) factors respondents considered before starting Lonca therapy, and (C) the number of Lonca cycles the typical patient received. For panel A, responses of “rarely,” “sometimes,” “often,” and “most of the time” were combined into yes. CAR‐T, chimeric antigen receptor T‐cell; DLBCL, diffuse large B‐cell lymphoma; Lonca, loncastuximab tesirine.</p></figcaption></figure><p>Respondents indicated that the most common considerations before choosing Lonca treatment were Lonca's tolerability profile (80%), Lonca's dosing and administration protocol (40%), and the patients' prior occurrences of cytopenia (27%). Other considerations (33%) included the patients' fitness and CD19 status, the efficacy of Lonca, the potential for using Lonca in patients with existing effusions, and the option for a clinical trial or other treatment (Figure <a href="#hon70128-fig-0001" class="usa-link">1B</a>). Most respondents (67%) stated their patients typically received 3 to 4 Lonca doses (Figure <a href="#hon70128-fig-0001" class="usa-link">1C</a>). Respondents indicated that unplanned discontinuations of Lonca occurred more commonly due to disease progression (80%) than because of AEs (20%).</p></section><section id="hon70128-sec-0110"><h3 class="pmc_sec_title">3.3. Adverse Event Patterns and Patient Counseling</h3>
<p>Respondents indicated edema was the most common AE (any grade) and that cutaneous reactions (including rashes and photosensitivity) were the most common severe AEs (grade ≥ 3) observed with Lonca in their clinical experience (Figure <a href="#hon70128-fig-0002" class="usa-link">2</a>). Other commonly reported AEs included fatigue, myelosuppression, pleural effusion, and other laboratory abnormalities, including chemistry changes. For patients who experienced a Lonca‐associated AE, respondents indicated that over a third experienced the AE after 1 to 2 doses (45% of patients) or 3 to 4 doses (45%).</p>
<figure class="fig xbox font-sm" id="hon70128-fig-0002"><h4 class="obj_head">FIGURE 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dec8/12368254/5a1e6548b4c5/HON-43-e70128-g001.jpg" loading="lazy" id="jats-graphic-3" height="332" width="709" alt="FIGURE 2"></p>
<div class="p text-right font-secondary"><a href="figure/hon70128-fig-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Respondent rating of (A) the most common adverse events of any grade or (B) the most common severe adverse events of any grade observed with using Lonca. Respondents ranked the adverse events from the most common (value of 10) to the least common (value 1) and were instructed to select “N/A” if they had not observed the adverse event with Lonca in their practice. AE, adverse event; GGT, gamma‐glutamyl transferase; Lonca, loncastuximab tesirine; N/A, not applicable.</p></figcaption></figure><p>Respondents indicated that when Lonca doses were reduced or held, myelosuppression/neutropenia was the most common reason for reducing (33%) or holding (33%) the Lonca dosage (Table <a href="#hon70128-tbl-0002" class="usa-link">2</a>). Respondents routinely provided counseling to patients receiving Lonca regarding sunlight exposure/protective measures (93%), shortness of breath (93%), fever or bruising/bleeding (80%), and periodic monitoring of blood counts (60%).</p>
<section class="tw xbox font-sm" id="hon70128-tbl-0002"><h4 class="obj_head">TABLE 2.</h4>
<div class="caption p"><p>Most common adverse events associated with Lonca dosage being reduced, held, or discontinued.<a href="#hon70128-note-0004" class="usa-link">
<sup>a</sup>
</a>
</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1"></th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Survey respondents (<em>N</em> = 15)</th>
</tr></thead>
<tbody valign="top">
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Most common reasons for Lonca dosage to be reduced, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">10 (66.7)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Myelosuppression/neutropenia</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (33.3)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Edema/third spacing<a href="#hon70128-note-0005" class="usa-link">
<sup>b</sup>
</a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (20.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Cutaneous reaction/rash</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (13.3)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Most common reasons for Lonca dosage to be held, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">14 (93.3)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Myelosuppression/neutropenia</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 (33.3%)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Edema/third spacing<a href="#hon70128-note-0005" class="usa-link">
<sup>b</sup>
</a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 (26.7)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Cutaneous reaction/rash</td>
<td align="center" valign="top" rowspan="1" colspan="1">4 (26.7)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Effusion</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (6.7)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Most common reasons for Lonca dosage to be discontinued, <em>n</em> (%)</td>
<td align="center" valign="top" rowspan="1" colspan="1">11 (73.3)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Pleural/pericardial effusion</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (20.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Progressive disease</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 (20.0)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Cutaneous reaction/rash</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (13.3)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Edema/third spacing<a href="#hon70128-note-0005" class="usa-link">
<sup>b</sup>
</a>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">2 (13.3)</td>
</tr>
<tr>
<td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Myelosuppression/neutropenia</td>
<td align="center" valign="top" rowspan="1" colspan="1">1 (6.7)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/hon70128-tbl-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="hon70128-note-0003"><p>Abbreviations: AE, adverse event; Lonca, loncastuximab tesirine.</p></div>
<div class="fn" id="hon70128-note-0004">
<sup>
<sup>a</sup>
</sup><p class="display-inline">Respondents were asked to indicate the primary reason for reducing, holding, or discontinuing Lonca dosage; as the question was a free‐response question, if 2 adverse events were provided, only the first was counted.</p>
</div>
<div class="fn" id="hon70128-note-0005">
<sup>
<sup>b</sup>
</sup><p class="display-inline">Category excludes pleural and pericardial effusions, which were collected separately.</p>
</div>
</div></section></section><section id="hon70128-sec-0120"><h3 class="pmc_sec_title">3.4. Lonca‐Associated Adverse Events</h3>
<p>Most respondents (93%) indicated that the majority (i.e., 76%–100%) of their patients were treated with prophylactic dexamethasone to manage edema/effusion. In response to being asked to estimate how often they encountered typical Lonca‐associated AEs, respondents indicated that peripheral edema was common, with most indicating it was observed in ≤ 50% of their patients and over a quarter indicating it was observed in &gt; 50% of their patients (Figure <a href="#hon70128-fig-0003" class="usa-link">3A</a>). In contrast, pleural and pericardial effusion were relatively rare, with approximately 73% and 93% of respondents, respectively, reporting ≤ 25% incidence of those AEs. When discontinuation of Lonca was required, it typically occurred after 3 to 4 doses of Lonca and was in response to peripheral edema, pleural effusion, hematological toxicity, cutaneous reactions, or pericardial effusion (Figure <a href="#hon70128-fig-0003" class="usa-link">3B</a>).</p>
<figure class="fig xbox font-sm" id="hon70128-fig-0003"><h4 class="obj_head">FIGURE 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dec8/12368254/4ce6d607f57e/HON-43-e70128-g004.jpg" loading="lazy" id="jats-graphic-5" height="372" width="709" alt="FIGURE 3"></p>
<div class="p text-right font-secondary"><a href="figure/hon70128-fig-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Respondent ratings of Lonca‐associated AEs, including (A) the percentage of patients who experienced Lonca‐associated AEs, (B) the number of Lonca treatment cycles before an AE led to discontinuation, and (C) the treatments used to manage AEs. For panel C, diuretics were not listed as a treatment option for Lonca‐associated hematological toxicity, but growth factor support was. Growth factor support was the only treatment option provided for hematological toxicity. Cutaneous reactions, such as rash or photosensitivity, were not plotted because their management options (i.e., antihistamines, topical steroids, systemic steroids) differed from those of other conditions. AE, adverse event; Lonca, loncastuximab tesirine.</p></figcaption></figure><p>When delaying a Lonca dose was necessary, respondents indicated that common reasons included management of pleural effusion, hematological toxicity, peripheral edema, or pericardial effusion (Figure <a href="#hon70128-fig-0003" class="usa-link">3C</a>). All respondents prescribed diuretics to manage peripheral edema; over half selected either spironolactone (60%) or loop diuretics (60%). When managing Lonca‐associated cutaneous reactions, most respondents used topical steroids (87%), followed by H2 blocking antihistamines (53%), H1 blocking antihistamines (47%), or systemic steroids (13%).</p></section><section id="hon70128-sec-0130"><h3 class="pmc_sec_title">3.5. Patient Concerns and Physician Perceptions</h3>
<p>The most common patient concerns reported by physicians were fatigue (47%) and photosensitivity (27%). Most respondents indicated that they thought Lonca has a comparable safety profile with other treatments for R/R DLBCL (60%), with just over a quarter indicating they thought Lonca has a more tolerable safety profile (27%), and one respondent indicating it was less tolerable (13%).</p></section></section><section id="hon70128-sec-0140"><h2 class="pmc_sec_title">4. Discussion</h2>
<p>The aim of this study was to offer clinical recommendations for managing AEs in patients receiving Lonca for R/R DLBCL based on input from US oncologists specializing in lymphoma. The survey results on Lonca safety and AE management were consistent with prior LOTIS trials, and respondents provided views that were generally aligned with the LOTIS trials, but with additional insights based on experiences outside of the LOTIS clinical trials in the era of widespread availability of CAR‐T and bispecific antibody therapies.</p>
<p>Physicians reported selecting Lonca both before and after bispecific antibodies. It should be noted, however, that the approval of bispecific antibodies in the US for DLBCL occurred only toward the middle of 2023 [<a href="#hon70128-bib-0016" class="usa-link" aria-describedby="hon70128-bib-0016">16</a>, <a href="#hon70128-bib-0017" class="usa-link" aria-describedby="hon70128-bib-0017">17</a>]. The optimal sequencing of bispecific antibodies in relation to other treatments, including CAR‐T, is still being studied. Some oncologists may prefer to use bispecific antibodies as a bridging therapy prior to CAR‐T, in combination with other therapies, as the next line of treatment after CAR‐T, or as an alternative for patients who progress after, are ineligible for, or lack access to CAR‐T [<a href="#hon70128-bib-0028" class="usa-link" aria-describedby="hon70128-bib-0028">28</a>, <a href="#hon70128-bib-0029" class="usa-link" aria-describedby="hon70128-bib-0029">29</a>].</p>
<p>To assist oncologists and other healthcare practitioners (HCPs) with the identification and management of Lonca‐associated AEs, we have developed an algorithm for managing the most common Lonca‐associated AEs, including edema, effusions, myelosuppression, cutaneous reactions (including rashes and photosensitivity), infections, along with liver function and laboratory abnormalities (Figure <a href="#hon70128-fig-0004" class="usa-link">4</a>). Most Lonca‐associated AEs appear relatively early during treatment (i.e., within 4 doses) with higher Lonca dosages and may abate once the Lonca dosage is reduced for subsequent cycles. In addition, as Lonca‐associated AEs are mostly predictable and easily identifiable, oncologists and advanced practice providers (i.e., registered nurse practitioners and physician assistants) can administer a focused, symptom‐based assessment of common symptoms, such as weight gain, swelling, fatigue, shortness of breath, and rash. As edema, effusions, myelosuppression, and rash are the primary reasons for Lonca dose delays or discontinuations, early intervention by HCPs using standardized protocols is recommended.</p>
<figure class="fig xbox font-sm" id="hon70128-fig-0004"><h3 class="obj_head">FIGURE 4.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dec8/12368254/4e64737598dc/HON-43-e70128-g002.jpg" loading="lazy" id="jats-graphic-7" height="432" width="709" alt="FIGURE 4"></p>
<div class="p text-right font-secondary"><a href="figure/hon70128-fig-0004/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Lonca treatment algorithm, including recommendations for patient monitoring and treatment strategies for oncologists. ALT, alanine aminotransferase; AST, aspartate aminotransferase; bid, twice daily; CBC, complete blood count; CrCl, creatinine clearance; G‐CSF, granulocyte colony–stimulating factor; GGT, gamma‐glutamyl transferase; HCP, healthcare practitioner; IV, intravenous; Lonca, loncastuximab tesirine; SPF, sun protection factor.</p></figcaption></figure><p>Specifically for edema and effusions, we recommend the consideration of spironolactone with an initial dose (i.e., 25–100 mg/day orally) based on edema severity and titrated as clinically indicated, with a potential addition of other agents (i.e., thiazide or loop diuretics) for more severe edema, hypertension, or in patients at risk for hyperkalemia. For cutaneous reactions, we recommend monitoring for common reactions (i.e., rash, redness, and itching) and patient education on common concerns (i.e., itching, photosensitivity, and sun exposure). For sun exposure, we recommend counseling patients to avoid direct sun exposure and use high sun‐protection factor sunscreen for at least 4 months after discontinuing Lonca to allow for drug clearance. Case studies have demonstrated that when managing cutaneous reactions, including photosensitivity rash, antihistamines (H1 and H2 blockers) and topical corticosteroids (i.e., clobetasol) can be used to diminish associated immune responses [<a href="#hon70128-bib-0030" class="usa-link" aria-describedby="hon70128-bib-0030">30</a>]. For more severe cutaneous reactions that do not respond to topical steroids and/or that have spread to other areas of the body, we recommend considering systemic steroids (i.e., prednisone taper starting at 0.5 mg/kg daily) and reducing or holding Lonca until symptom resolution [<a href="#hon70128-bib-0031" class="usa-link" aria-describedby="hon70128-bib-0031">31</a>]. Also, we recommend alerting patients about the use of dexamethasone before treatment to prevent PBD‐related toxicities (i.e., edema and rash). For infection management, we propose the use of a growth factor (i.e., granulocyte colony–stimulating factor) for patients with infection secondary to neutropenia. Across all these AEs, patient education is important, so patients can recognize and report relevant symptoms to allow for early treatment intervention.</p>
<p>This study has several limitations, including responses predominantly from academic centers, which may affect the generalizability of the findings as the usage pattern of Lonca and clinical management may vary between the academic and community settings. Additionally, responses were somewhat qualitative in nature, and the ranges of patient experience were broad (e.g., 44% of respondents reporting treating 1 to 5 DLBCL patients with DLBCL using Lonca), so the percentages may not accurately reflect the actual clinical prevalence of Lonca‐associated AEs. However, the study has notable strengths, including the collection of responses across a diverse selection of respondents located in the US and input from actively practicing oncologists specializing in DLBCL, ensuring that the feedback comes from experts in lymphoma management.</p></section><section id="hon70128-sec-0150"><h2 class="pmc_sec_title">5. Conclusion</h2>
<p>Based on the results of a survey of US oncologists specializing in lymphoma, including DLBCL, Lonca‐associated AEs are manageable in a variety of clinical settings. This aligns with prior real‐world data which have also demonstrated that Lonca can be administered effectively in community practices [<a href="#hon70128-bib-0026" class="usa-link" aria-describedby="hon70128-bib-0026">26</a>]. The survey findings were consistent with prior LOTIS clinical trials, indicating the tolerability of Lonca in real‐world practice. Respondents provided largely similar opinions on the management of key AEs, such as edema, effusions, myelosuppression, and cutaneous reactions, indicating a similar approach across different settings. Overall, we found that Lonca‐associated AEs can be effectively managed by oncologists practicing in the community setting, supporting its broader use in clinical practice. This article provides a comprehensive overview of Lonca use and AE management and serves as a quick reference for oncologists planning to treat patients diagnosed with R/R DLBCL with Lonca.</p></section><section id="hon70128-sec-0160"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>N.E., A.J.O., S.A., and E.C.A. contributed to the development and distribution of the survey. All authors were involved in the design and formulation of the survey questions and ensured its appropriate dissemination to the target audience. N.E. led the coordination of survey distribution across various centers, while A.J.O., S.A., and E.C.A. provided critical input in refining the survey content. The authors did not receive compensation for their contributions to the survey. All authors participated in the interpretation of the survey results, as well as the revision of the manuscript. Finally, all authors reviewed and gave final approval of the submitted manuscript.</p></section><section id="hon70128-sec-0180"><h2 class="pmc_sec_title">Ethics Statement</h2>
<p>The study was conducted in compliance with the Declaration of Helsinki. Given the nature of the study (survey), this study was IRB exempt.</p></section><section id="hon70128-sec-0190"><h2 class="pmc_sec_title">Consent</h2>
<p>Informed consent was waived.</p></section><section id="hon70128-sec-0200"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>N.E.: Research support to the institution for clinical trials from BeiGene, Incyte, Lilly, Ipsen, ADC Therapeutics; Ad boards for Ipsen, Genentech, and CRISPR Therapeutics. A.J.O.: Clinical research scholar of the Leukemia and Lymphoma Society; reports consultancy role with Genmab, Schrodinger, Blue Cross and Blue Shield of Rhode Island, Bristol‐Myers Squibb, and ADC Therapeutics; and receives research funding from Adaptive Biotechnologies. E.C.A.: Research funding from Abbvie, ADC Therapeutics, Regeneron, and Lilly. Consultancy for ADC Therapeutics and Bristol‐Myers Squibb. S.A.: Research support to institution for clinical trials from Nektar, Merck, Xencor, Chimagen and Genmab; has membership on Chimagen scientific advisory committee; serves on data safety monitoring board for Myeloid Therapeutics; and is a consultant for ADC Therapeutics and KITE/Gilead.</p></section><section id="hon70128-sec-0230"><h2 class="pmc_sec_title">Peer Review</h2>
<p>The peer review history for this article is available at <a href="https://www.webofscience.com/api/gateway/wos/peer-review/10.1002/hon.70128" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.webofscience.com/api/gateway/wos/peer-review/10.1002/hon.70128</a>.</p></section><section id="hon70128-sec-0170" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>Medical writing support was provided by Nathan Hutcheson, PhD, CMPP, from Citrus Health Group Inc. (Chicago, Illinois, USA), and was funded by ADC Therapeutics SA (Murray Hill, New Jersey, USA) and Sobi (Stockholm, Sweden) in accordance with Good Publication Practice (GPP) guidelines. Also, we would like to thank all respondents for their time and effort in completing the survey.</p></section><section id="notes1"><p>


Epperla, Narendranath
, Olszewski Adam J., Ayers Emily C., and Ahmed Sairah. 2025. “Management of Adverse Reactions to Loncastuximab in Patients With Relapsed or Refractory Diffuse Large B‐Cell Lymphoma.”
Hematological Oncology: e70128. 10.1002/hon.70128.
</p>
<section id="fn-group1" class="fn-group"><div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="hon70128-note-0001"><p>
<strong>Funding:</strong> The authors received no specific funding for this work.</p></div></div></section></section><section id="hon70128-sec-0220"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>Data is available upon request to the corresponding author within the limits of the participant confidentiality.</p></section><section id="hon70128-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="hon70128-bibl-0001_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="hon70128-bib-0001">
<span class="label">1.</span><cite>
Cai W., Zeng Q., Zhang X., and Ruan W., “Trends Analysis of Non‐Hodgkin Lymphoma at the National, Regional, and Global Level, 1990‐2019: Results from the Global Burden of Disease Study 2019,” Frontiers of Medicine
8 (2021): 738693, 10.3389/fmed.2021.738693.</cite> [<a href="https://doi.org/10.3389/fmed.2021.738693" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8494781/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34631756/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20of%20Medicine&amp;title=Trends%20Analysis%20of%20Non%E2%80%90Hodgkin%20Lymphoma%20at%20the%20National,%20Regional,%20and%20Global%20Level,%201990%E2%80%902019:%20Results%20from%20the%20Global%20Burden%20of%20Disease%20Study%202019&amp;author=W.%20Cai&amp;author=Q.%20Zeng&amp;author=X.%20Zhang&amp;author=W.%20Ruan&amp;volume=8&amp;publication_year=2021&amp;pages=738693&amp;pmid=34631756&amp;doi=10.3389/fmed.2021.738693&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0002">
<span class="label">2.</span><cite>
Thandra K. C., Barsouk A., Saginala K., Padala S. A., Barsouk A., and Rawla P., “Epidemiology of Non‐Hodgkin's Lymphoma,” Medical Science
9, no. 1 (2021): 5, 10.3390/medsci9010005.</cite> [<a href="https://doi.org/10.3390/medsci9010005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7930980/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33573146/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Medical%20Science&amp;title=Epidemiology%20of%20Non%E2%80%90Hodgkin's%20Lymphoma&amp;author=K.%20C.%20Thandra&amp;author=A.%20Barsouk&amp;author=K.%20Saginala&amp;author=S.%20A.%20Padala&amp;author=A.%20Barsouk&amp;volume=9&amp;issue=1&amp;publication_year=2021&amp;pages=5&amp;pmid=33573146&amp;doi=10.3390/medsci9010005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0003">
<span class="label">3.</span><cite>
National Comprehensive Cancer Network
, “NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for B‐Cell Lymphomas V.2.2025,” National Comprehensive Cancer Network (2025).</cite> [<a href="https://doi.org/10.6004/jnccn.2004.0021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19795607/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=National%20Comprehensive%20Cancer%20Network&amp;title=NCCN%20Clinical%20Practice%20Guidelines%20in%20Oncology%20(NCCN%20Guidelines)%20for%20B%E2%80%90Cell%20Lymphomas%20V.2.2025&amp;publication_year=2025&amp;pmid=19795607&amp;doi=10.6004/jnccn.2004.0021&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0004">
<span class="label">4.</span><cite>
Sehn L. H. and Salles G., “Diffuse Large B‐cell Lymphoma,” New England Journal of Medicine
384, no. 9 (2021): 842–858, 10.1056/nejmra2027612.
</cite> [<a href="https://doi.org/10.1056/nejmra2027612" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8377611/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33657296/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=Diffuse%20Large%20B%E2%80%90cell%20Lymphoma&amp;author=L.%20H.%20Sehn&amp;author=G.%20Salles&amp;volume=384&amp;issue=9&amp;publication_year=2021&amp;pages=842-858&amp;pmid=33657296&amp;doi=10.1056/nejmra2027612&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0005">
<span class="label">5.</span><cite>
Coiffier B., Lepage E., Briere J., et al., “CHOP Chemotherapy plus Rituximab Compared With CHOP Alone in Elderly Patients With Diffuse large‐B‐cell Lymphoma,” New England Journal of Medicine
346, no. 4 (2002): 235–242, 10.1056/nejmoa011795.
</cite> [<a href="https://doi.org/10.1056/nejmoa011795" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11807147/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=CHOP%20Chemotherapy%20plus%20Rituximab%20Compared%20With%20CHOP%20Alone%20in%20Elderly%20Patients%20With%20Diffuse%20large%E2%80%90B%E2%80%90cell%20Lymphoma&amp;author=B.%20Coiffier&amp;author=E.%20Lepage&amp;author=J.%20Briere&amp;volume=346&amp;issue=4&amp;publication_year=2002&amp;pages=235-242&amp;pmid=11807147&amp;doi=10.1056/nejmoa011795&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0006">
<span class="label">6.</span><cite>
Habermann T. M., Weller E. A., Morrison V. A., et al., “Rituximab‐CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B‐cell Lymphoma,” Journal of Clinical Oncology
24, no. 19 (2006): 3121–3127, 10.1200/jco.2005.05.1003.
</cite> [<a href="https://doi.org/10.1200/jco.2005.05.1003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16754935/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Rituximab%E2%80%90CHOP%20Versus%20CHOP%20Alone%20or%20With%20Maintenance%20Rituximab%20in%20Older%20Patients%20With%20Diffuse%20Large%20B%E2%80%90cell%20Lymphoma&amp;author=T.%20M.%20Habermann&amp;author=E.%20A.%20Weller&amp;author=V.%20A.%20Morrison&amp;volume=24&amp;issue=19&amp;publication_year=2006&amp;pages=3121-3127&amp;pmid=16754935&amp;doi=10.1200/jco.2005.05.1003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0007">
<span class="label">7.</span><cite>
Tilly H., Morschhauser F., Sehn L. H., et al., “Polatuzumab Vedotin in Previously Untreated Diffuse Large B‐cell Lymphoma,” New England Journal of Medicine
386, no. 4 (2022): 351–363, 10.1056/nejmoa2115304.
</cite> [<a href="https://doi.org/10.1056/nejmoa2115304" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11702892/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34904799/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=Polatuzumab%20Vedotin%20in%20Previously%20Untreated%20Diffuse%20Large%20B%E2%80%90cell%20Lymphoma&amp;author=H.%20Tilly&amp;author=F.%20Morschhauser&amp;author=L.%20H.%20Sehn&amp;volume=386&amp;issue=4&amp;publication_year=2022&amp;pages=351-363&amp;pmid=34904799&amp;doi=10.1056/nejmoa2115304&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0008">
<span class="label">8.</span><cite>
Coiffier B., Thieblemont C., Van Den Neste E., et al., “Long‐term Outcome of Patients in the LNH‐98.5 Trial, the First Randomized Study Comparing rituximab‐CHOP to Standard CHOP Chemotherapy in DLBCL Patients: A Study by the Groupe D'Etudes Des Lymphomes De L'Adulte,” Blood
116, no. 12 (2010): 2040–2045, 10.1182/blood-2010-03-276246.
</cite> [<a href="https://doi.org/10.1182/blood-2010-03-276246" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2951853/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20548096/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Long%E2%80%90term%20Outcome%20of%20Patients%20in%20the%20LNH%E2%80%9098.5%20Trial,%20the%20First%20Randomized%20Study%20Comparing%20rituximab%E2%80%90CHOP%20to%20Standard%20CHOP%20Chemotherapy%20in%20DLBCL%20Patients:%20A%20Study%20by%20the%20Groupe%20D'Etudes%20Des%20Lymphomes%20De%20L'Adulte&amp;author=B.%20Coiffier&amp;author=C.%20Thieblemont&amp;author=E.%20Van%20Den%20Neste&amp;volume=116&amp;issue=12&amp;publication_year=2010&amp;pages=2040-2045&amp;pmid=20548096&amp;doi=10.1182/blood-2010-03-276246&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0009">
<span class="label">9.</span><cite>
Locke F. L., Miklos D. B., Jacobson C. A., et al., “Axicabtagene Ciloleucel as second‐line Therapy for Large B‐cell Lymphoma,” New England Journal of Medicine
386, no. 7 (2022): 640–654, 10.1056/nejmoa2116133.
</cite> [<a href="https://doi.org/10.1056/nejmoa2116133" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34891224/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=Axicabtagene%20Ciloleucel%20as%20second%E2%80%90line%20Therapy%20for%20Large%20B%E2%80%90cell%20Lymphoma&amp;author=F.%20L.%20Locke&amp;author=D.%20B.%20Miklos&amp;author=C.%20A.%20Jacobson&amp;volume=386&amp;issue=7&amp;publication_year=2022&amp;pages=640-654&amp;pmid=34891224&amp;doi=10.1056/nejmoa2116133&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0010">
<span class="label">10.</span><cite>
Abramson J. S., Solomon S. R., Arnason J., et al., “Lisocabtagene Maraleucel as second‐line Therapy for Large B‐cell Lymphoma: Primary Analysis of the Phase 3 TRANSFORM Study,” Blood
141, no. 14 (2023): 1675–1684, 10.1182/blood.2022018730.
</cite> [<a href="https://doi.org/10.1182/blood.2022018730" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10646768/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36542826/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Lisocabtagene%20Maraleucel%20as%20second%E2%80%90line%20Therapy%20for%20Large%20B%E2%80%90cell%20Lymphoma:%20Primary%20Analysis%20of%20the%20Phase%203%20TRANSFORM%20Study&amp;author=J.%20S.%20Abramson&amp;author=S.%20R.%20Solomon&amp;author=J.%20Arnason&amp;volume=141&amp;issue=14&amp;publication_year=2023&amp;pages=1675-1684&amp;pmid=36542826&amp;doi=10.1182/blood.2022018730&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0011">
<span class="label">11.</span><cite>
Kalakonda N., Maerevoet M., Cavallo F., et al., “Selinexor in Patients With Relapsed or Refractory Diffuse Large B‐cell Lymphoma (SADAL): A Single‐Arm, Multinational, Multicentre, Open‐Label, Phase 2 Trial,” Lancet Haematol
7 (2020): e511–e522, 10.1016/s2352-3026(20)30120-4.
</cite> [<a href="https://doi.org/10.1016/s2352-3026(20)30120-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32589977/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Haematol&amp;title=Selinexor%20in%20Patients%20With%20Relapsed%20or%20Refractory%20Diffuse%20Large%20B%E2%80%90cell%20Lymphoma%20(SADAL):%20A%20Single%E2%80%90Arm,%20Multinational,%20Multicentre,%20Open%E2%80%90Label,%20Phase%202%20Trial&amp;author=N.%20Kalakonda&amp;author=M.%20Maerevoet&amp;author=F.%20Cavallo&amp;volume=7&amp;publication_year=2020&amp;pages=e511-e522&amp;pmid=32589977&amp;doi=10.1016/s2352-3026(20)30120-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0012">
<span class="label">12.</span><cite>
Caimi P. F., Ai W., Alderuccio J. P., et al., “Loncastuximab Tesirine in Relapsed or Refractory Diffuse Large B‐cell Lymphoma (LOTIS‐2): A Multicentre, open‐label, single‐arm, Phase 2 Trial,” Lancet Oncology
22, no. 6 (2021): 790–800, 10.1016/s1470-2045(21)00139-x.
</cite> [<a href="https://doi.org/10.1016/s1470-2045(21)00139-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33989558/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncology&amp;title=Loncastuximab%20Tesirine%20in%20Relapsed%20or%20Refractory%20Diffuse%20Large%20B%E2%80%90cell%20Lymphoma%20(LOTIS%E2%80%902):%20A%20Multicentre,%20open%E2%80%90label,%20single%E2%80%90arm,%20Phase%202%20Trial&amp;author=P.%20F.%20Caimi&amp;author=W.%20Ai&amp;author=J.%20P.%20Alderuccio&amp;volume=22&amp;issue=6&amp;publication_year=2021&amp;pages=790-800&amp;pmid=33989558&amp;doi=10.1016/s1470-2045(21)00139-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0013">
<span class="label">13.</span><cite>
Bartlett N. L., Yasenchak C. A., Ashraf K., Harwin W., Sims R., and Nowakowski G. S., “Brentuximab Vedotin in Combination With Lenalidomide and Rituximab in Patients With Relapsed or Refractory Diffuse Large B‐cell Lymphoma (DLBCL)(ECHELON‐3, Trial in Progress),” supplement, Blood
138, no. S1 (2021): 3564, 10.1182/blood-2021-151583.</cite> [<a href="https://doi.org/10.1182/blood-2021-151583" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Brentuximab%20Vedotin%20in%20Combination%20With%20Lenalidomide%20and%20Rituximab%20in%20Patients%20With%20Relapsed%20or%20Refractory%20Diffuse%20Large%20B%E2%80%90cell%20Lymphoma%20(DLBCL)(ECHELON%E2%80%903,%20Trial%20in%20Progress)&amp;author=N.%20L.%20Bartlett&amp;author=C.%20A.%20Yasenchak&amp;author=K.%20Ashraf&amp;author=W.%20Harwin&amp;author=R.%20Sims&amp;volume=138&amp;issue=S1&amp;publication_year=2021&amp;pages=3564&amp;doi=10.1182/blood-2021-151583&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0014">
<span class="label">14.</span><cite>
Neelapu S. S., Locke F. L., Bartlett N. L., et al., “Axicabtagene Ciloleucel CAR T‐cell Therapy in Refractory Large B‐cell Lymphoma,” New England Journal of Medicine
377, no. 26 (2017): 2531–2544, 10.1056/nejmoa1707447.
</cite> [<a href="https://doi.org/10.1056/nejmoa1707447" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5882485/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29226797/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=Axicabtagene%20Ciloleucel%20CAR%20T%E2%80%90cell%20Therapy%20in%20Refractory%20Large%20B%E2%80%90cell%20Lymphoma&amp;author=S.%20S.%20Neelapu&amp;author=F.%20L.%20Locke&amp;author=N.%20L.%20Bartlett&amp;volume=377&amp;issue=26&amp;publication_year=2017&amp;pages=2531-2544&amp;pmid=29226797&amp;doi=10.1056/nejmoa1707447&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0015">
<span class="label">15.</span><cite>
Abramson J. S., Palomba M. L., Gordon L. I., et al., “Lisocabtagene Maraleucel for Patients With Relapsed or Refractory Large B‐cell Lymphomas (TRANSCEND NHL 001): A Multicentre Seamless Design Study,” Lancet
396, no. 10254 (2020): 839–852, 10.1016/s0140-6736(20)31366-0.
</cite> [<a href="https://doi.org/10.1016/s0140-6736(20)31366-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32888407/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Lisocabtagene%20Maraleucel%20for%20Patients%20With%20Relapsed%20or%20Refractory%20Large%20B%E2%80%90cell%20Lymphomas%20(TRANSCEND%20NHL%20001):%20A%20Multicentre%20Seamless%20Design%20Study&amp;author=J.%20S.%20Abramson&amp;author=M.%20L.%20Palomba&amp;author=L.%20I.%20Gordon&amp;volume=396&amp;issue=10254&amp;publication_year=2020&amp;pages=839-852&amp;pmid=32888407&amp;doi=10.1016/s0140-6736(20)31366-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0016">
<span class="label">16.</span><cite>
Thieblemont C., Phillips T., Ghesquieres H., et al., “Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T‐cell‐engaging Antibody, in Relapsed or Refractory Large B‐cell Lymphoma: Dose Expansion in a Phase I/II Trial,” Journal of Clinical Oncology
41, no. 12 (2023): 2238–2247, 10.1200/jco.22.01725.
</cite> [<a href="https://doi.org/10.1200/jco.22.01725" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10115554/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36548927/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Epcoritamab,%20a%20Novel,%20Subcutaneous%20CD3xCD20%20Bispecific%20T%E2%80%90cell%E2%80%90engaging%20Antibody,%20in%20Relapsed%20or%20Refractory%20Large%20B%E2%80%90cell%20Lymphoma:%20Dose%20Expansion%20in%20a%20Phase%20I/II%20Trial&amp;author=C.%20Thieblemont&amp;author=T.%20Phillips&amp;author=H.%20Ghesquieres&amp;volume=41&amp;issue=12&amp;publication_year=2023&amp;pages=2238-2247&amp;pmid=36548927&amp;doi=10.1200/jco.22.01725&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0017">
<span class="label">17.</span><cite>
Dickinson M. J., Carlo‐Stella C., Morschhauser F., et al., “Glofitamab for Relapsed or Refractory Diffuse Large B‐cell Lymphoma,” New England Journal of Medicine
387, no. 24 (2022): 2220–2231, 10.1056/nejmoa2206913.
</cite> [<a href="https://doi.org/10.1056/nejmoa2206913" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36507690/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=Glofitamab%20for%20Relapsed%20or%20Refractory%20Diffuse%20Large%20B%E2%80%90cell%20Lymphoma&amp;author=M.%20J.%20Dickinson&amp;author=C.%20Carlo%E2%80%90Stella&amp;author=F.%20Morschhauser&amp;volume=387&amp;issue=24&amp;publication_year=2022&amp;pages=2220-2231&amp;pmid=36507690&amp;doi=10.1056/nejmoa2206913&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0018">
<span class="label">18.</span><cite>
Salles G., Duell J., Gonzalez Barca E., et al., “Tafasitamab plus Lenalidomide in Relapsed or Refractory Diffuse Large B‐cell Lymphoma (L‐MIND): A Multicentre, Prospective, Single‐Arm, Phase 2 Study,” Lancet Oncology
21, no. 7 (2020): 978–988, 10.1016/s1470-2045(20)30225-4.
</cite> [<a href="https://doi.org/10.1016/s1470-2045(20)30225-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32511983/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncology&amp;title=Tafasitamab%20plus%20Lenalidomide%20in%20Relapsed%20or%20Refractory%20Diffuse%20Large%20B%E2%80%90cell%20Lymphoma%20(L%E2%80%90MIND):%20A%20Multicentre,%20Prospective,%20Single%E2%80%90Arm,%20Phase%202%20Study&amp;author=G.%20Salles&amp;author=J.%20Duell&amp;author=E.%20Gonzalez%20Barca&amp;volume=21&amp;issue=7&amp;publication_year=2020&amp;pages=978-988&amp;pmid=32511983&amp;doi=10.1016/s1470-2045(20)30225-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0019">
<span class="label">19.</span><cite>
Shadman M., Ahn K. W., Kaur M., et al., “Autologous Transplant Vs. CAR‐T Therapy in Patients With DLBCL Treated While in Complete Remission,” Blood Cancer Journal
14, no. 1 (2024): 108, 10.1038/s41408-024-01084-w.
</cite> [<a href="https://doi.org/10.1038/s41408-024-01084-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11231252/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38977682/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Cancer%20Journal&amp;title=Autologous%20Transplant%20Vs.%20CAR%E2%80%90T%20Therapy%20in%20Patients%20With%20DLBCL%20Treated%20While%20in%20Complete%20Remission&amp;author=M.%20Shadman&amp;author=K.%20W.%20Ahn&amp;author=M.%20Kaur&amp;volume=14&amp;issue=1&amp;publication_year=2024&amp;pages=108&amp;pmid=38977682&amp;doi=10.1038/s41408-024-01084-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0020">
<span class="label">20.</span><cite>
Shadman M., Pasquini M., Ahn K. W., et al., “Autologous Transplant Vs Chimeric Antigen Receptor T‐cell Therapy for Relapsed DLBCL in Partial Remission,” Blood
139 (2022): 1330–1339, 10.1182/blood.2021013289.
</cite> [<a href="https://doi.org/10.1182/blood.2021013289" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8900276/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34570879/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Autologous%20Transplant%20Vs%20Chimeric%20Antigen%20Receptor%20T%E2%80%90cell%20Therapy%20for%20Relapsed%20DLBCL%20in%20Partial%20Remission&amp;author=M.%20Shadman&amp;author=M.%20Pasquini&amp;author=K.%20W.%20Ahn&amp;volume=139&amp;publication_year=2022&amp;pages=1330-1339&amp;pmid=34570879&amp;doi=10.1182/blood.2021013289&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0021">
<span class="label">21.</span><cite>
Calabretta E., Hamadani M., Zinzani P. L., Caimi P., and Carlo‐Stella C., “The antibody‐drug Conjugate Loncastuximab Tesirine for the Treatment of Diffuse Large B‐cell Lymphoma,” Blood
140, no. 4 (2022): 303–308, 10.1182/blood.2021014663.
</cite> [<a href="https://doi.org/10.1182/blood.2021014663" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9335500/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35580172/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=The%20antibody%E2%80%90drug%20Conjugate%20Loncastuximab%20Tesirine%20for%20the%20Treatment%20of%20Diffuse%20Large%20B%E2%80%90cell%20Lymphoma&amp;author=E.%20Calabretta&amp;author=M.%20Hamadani&amp;author=P.%20L.%20Zinzani&amp;author=P.%20Caimi&amp;author=C.%20Carlo%E2%80%90Stella&amp;volume=140&amp;issue=4&amp;publication_year=2022&amp;pages=303-308&amp;pmid=35580172&amp;doi=10.1182/blood.2021014663&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0022">
<span class="label">22.</span><cite>
Zammarchi F., Corbett S., Adams L., et al., “ADCT‐402, a PBD dimer‐containing Antibody Drug Conjugate Targeting CD19‐expressing Malignancies,” Blood
131, no. 10 (2018): 1094–1105, 10.1182/blood-2017-10-813493.
</cite> [<a href="https://doi.org/10.1182/blood-2017-10-813493" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29298756/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=ADCT%E2%80%90402,%20a%20PBD%20dimer%E2%80%90containing%20Antibody%20Drug%20Conjugate%20Targeting%20CD19%E2%80%90expressing%20Malignancies&amp;author=F.%20Zammarchi&amp;author=S.%20Corbett&amp;author=L.%20Adams&amp;volume=131&amp;issue=10&amp;publication_year=2018&amp;pages=1094-1105&amp;pmid=29298756&amp;doi=10.1182/blood-2017-10-813493&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0023">
<span class="label">23.</span><cite>
US Food and Drug Administration
. ZYNLONTA. Loncastuximab tesirine‐lpyl (ADC Therapeutics, 2022).</cite> [<a href="https://scholar.google.com/scholar_lookup?title=ZYNLONTA.%20Loncastuximab%20tesirine%E2%80%90lpyl&amp;publication_year=2022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0024">
<span class="label">24.</span><cite>
US Food and Drug Administration
. Drugs@Fda: Fda‐Approved Drugs, accessed April 8, 2025, <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process%26varApplNo=761196" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=761196</a>.</cite>
</li>
<li id="hon70128-bib-0025">
<span class="label">25.</span><cite>
Caimi P. F., Ai W. Z., Alderuccio J. P., et al., “Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐cell Lymphoma: Long‐Term Efficacy and Safety From the Phase II LOTIS‐2 Study,” Haematologica
109, no. 4 (2024): 1184–1193, 10.3324/haematol.2023.283459.
</cite> [<a href="https://doi.org/10.3324/haematol.2023.283459" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10985439/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37646659/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Haematologica&amp;title=Loncastuximab%20Tesirine%20in%20Relapsed/Refractory%20Diffuse%20Large%20B%E2%80%90cell%20Lymphoma:%20Long%E2%80%90Term%20Efficacy%20and%20Safety%20From%20the%20Phase%20II%20LOTIS%E2%80%902%20Study&amp;author=P.%20F.%20Caimi&amp;author=W.%20Z.%20Ai&amp;author=J.%20P.%20Alderuccio&amp;volume=109&amp;issue=4&amp;publication_year=2024&amp;pages=1184-1193&amp;pmid=37646659&amp;doi=10.3324/haematol.2023.283459&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0026">
<span class="label">26.</span><cite>
Epperla N., Lucero M., Bailey T., et al., “Outcomes With Loncastuximab Tesirine Following CAR T‐Cell Therapy in Patients With Relapsed or Refractory Diffuse Large B‐Cell Lymphoma,” Blood Cancer Journal
14, no. 1 (2024): 210, 10.1038/s41408-024-01195-4.
</cite> [<a href="https://doi.org/10.1038/s41408-024-01195-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11604956/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39609431/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Cancer%20Journal&amp;title=Outcomes%20With%20Loncastuximab%20Tesirine%20Following%20CAR%20T%E2%80%90Cell%20Therapy%20in%20Patients%20With%20Relapsed%20or%20Refractory%20Diffuse%20Large%20B%E2%80%90Cell%20Lymphoma&amp;author=N.%20Epperla&amp;author=M.%20Lucero&amp;author=T.%20Bailey&amp;volume=14&amp;issue=1&amp;publication_year=2024&amp;pages=210&amp;pmid=39609431&amp;doi=10.1038/s41408-024-01195-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0027">
<span class="label">27.</span><cite>
Zelikson V., Gurumurthi A., Sawalha Y., et al., “Loncastuximab in high‐risk and Heavily Pretreated Relapsed/Refractory Diffuse Large B‐cell Lymphoma: A real‐world Analysis from 21 US Centers,” Haematologica
110, no. 3 (2024): 0–714, 10.3324/haematol.2024.285977.</cite> [<a href="https://doi.org/10.3324/haematol.2024.285977" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11873705/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39540227/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Haematologica&amp;title=Loncastuximab%20in%20high%E2%80%90risk%20and%20Heavily%20Pretreated%20Relapsed/Refractory%20Diffuse%20Large%20B%E2%80%90cell%20Lymphoma:%20A%20real%E2%80%90world%20Analysis%20from%2021%20US%20Centers&amp;author=V.%20Zelikson&amp;author=A.%20Gurumurthi&amp;author=Y.%20Sawalha&amp;volume=110&amp;issue=3&amp;publication_year=2024&amp;pages=0-714&amp;pmid=39540227&amp;doi=10.3324/haematol.2024.285977&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0028">
<span class="label">28.</span><cite>
Trabolsi A., Arumov A., and Schatz J. H., “Bispecific Antibodies and CAR‐T Cells: Dueling Immunotherapies for Large B‐cell Lymphomas,” Blood Cancer Journal
14, no. 1 (2024): 27, 10.1038/s41408-024-00997-w.
</cite> [<a href="https://doi.org/10.1038/s41408-024-00997-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10853226/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38331870/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Cancer%20Journal&amp;title=Bispecific%20Antibodies%20and%20CAR%E2%80%90T%20Cells:%20Dueling%20Immunotherapies%20for%20Large%20B%E2%80%90cell%20Lymphomas&amp;author=A.%20Trabolsi&amp;author=A.%20Arumov&amp;author=J.%20H.%20Schatz&amp;volume=14&amp;issue=1&amp;publication_year=2024&amp;pages=27&amp;pmid=38331870&amp;doi=10.1038/s41408-024-00997-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0029">
<span class="label">29.</span><cite>
Hutchings M., “The Evolving Therapy of DLBCL: Bispecific Antibodies,” supplement, Hematological Oncology
41, no. S1 (2023): 107–111, 10.1002/hon.3154.
</cite> [<a href="https://doi.org/10.1002/hon.3154" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37294965/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hematological%20Oncology&amp;title=The%20Evolving%20Therapy%20of%20DLBCL:%20Bispecific%20Antibodies&amp;author=M.%20Hutchings&amp;volume=41&amp;issue=S1&amp;publication_year=2023&amp;pages=107-111&amp;pmid=37294965&amp;doi=10.1002/hon.3154&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="hon70128-bib-0030">
<span class="label">30.</span><cite>
Mistry H. and Ahmed S., 2022. “Case Study: Photosensitivity Rash Associated With Loncastuximab Teserine. Presented At: Pan Pacific Lymphoma Conference.”</cite>
</li>
<li id="hon70128-bib-0031">
<span class="label">31.</span><cite>
Seervai R. N. H., Okada C. Y., Mengden‐Koon S. J., and Hornick N. I., “Vesiculobullous Eruption With Loncastuximab Tesirine in a Patient With Relapsed Follicular Lymphoma,” JAAD Case Reports
53 (2024): 1–5, 10.1016/j.jdcr.2024.08.013.
</cite> [<a href="https://doi.org/10.1016/j.jdcr.2024.08.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11480243/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39421259/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAAD%20Case%20Reports&amp;title=Vesiculobullous%20Eruption%20With%20Loncastuximab%20Tesirine%20in%20a%20Patient%20With%20Relapsed%20Follicular%20Lymphoma&amp;author=R.%20N.%20H.%20Seervai&amp;author=C.%20Y.%20Okada&amp;author=S.%20J.%20Mengden%E2%80%90Koon&amp;author=N.%20I.%20Hornick&amp;volume=53&amp;publication_year=2024&amp;pages=1-5&amp;pmid=39421259&amp;doi=10.1016/j.jdcr.2024.08.013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>Data is available upon request to the corresponding author within the limits of the participant confidentiality.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Hematological Oncology are provided here courtesy of <strong>Wiley</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1002/hon.70128"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/HON-43-e70128.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.1 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12368254/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12368254/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12368254%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368254/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12368254/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12368254/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40836271/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12368254/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40836271/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12368254/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12368254/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="pLzH117vo2dPCCh2zxvuNLRBOV7D7QrMkcwKv2TOmTkCGwZVHEDsznDYQqkLSeUp">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
